Soligenix reports safety milestone in phase 3 CTCL treatment trial
PositiveFinancial Markets

Soligenix has announced a significant safety milestone in its Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma (CTCL). This achievement is crucial as it not only demonstrates the potential effectiveness of their treatment but also reassures patients and investors about the safety of the drug. Positive results from such trials can lead to advancements in treatment options for patients suffering from this challenging condition.
— Curated by the World Pulse Now AI Editorial System